Navigation

Clininal Study Reporting Guidelines

ad

   
Randomized trials (CONSORT)
Observational studies (STROBE)
Systematic reviews (PRISMA)
Case reports (CARE)
Qualitative research (SRQR
Diagnostic / prognostic studies (STARD)
Quality improvement studies (SQUIRE)
Economic evaluations (CHEERS)  
Animal pre-clinical studies (ARRIVE)
Study protocols (SPIRIT)
Clinical practice guidelines (AGREE)


Read more...

Publishing Policy


Elmer Press Publishing Policies, and Guidelines to follow, click for details......

Advertising

ad
Our journals are open access, which means all the contents of the journals are accessible freely to all viewers from every part of the world as long as they have internet accessibility, More...

Contact Us

 

Elmer Press Inc.
9225 Leslie Street, Suite 201
Richmond Hill
Ontario, L4B 3H6
Canada
Tel:  647-671-2629
Fax: 647-498-1289


            
elmerpublisher@hotmail.com (alternative email)

Selected Publications

Jan 5, 2022

Management of Male Breast Cancer: The Journey so Far and Future Directions
By Quratulain (Anna) Sabih et al. World Journal of Oncology, Vol. 12, No. 6, Dec 2021

Male breast cancer is now shown to be a unique entity and should be considered as a distinct disease. Given the relatively smaller number of cases, randomized controlled trials for treatment are extremely limited and majority of practices are derived from female breast cancer studies.  Read More.... 
 

Jan 5, 2022
Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers
 
By Marilena Greco et al. Journal of Clinical Medicine Research, Vol. 13, No. 12, Dec 2021

Vaccine-induced immunity is at present the main strategy to stop the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent evidences suggested a protective effect of influenza vaccination against coronavirus disease 2019 (COVID-19) severity, while impact on the immune response to BNT162b2 messenger RNA (mRNA) vaccine is under investigation.  Read More.... 

 

Dec 21, 2021

Pulmonary Toxicity of Hodgkin Lymphoma Treatment: A Prospective Single-Center Study 
By Adam Jona et al. Journal of Hematology, Vol. 10, No. 6, Dec 2021

Standard bleomycin-containing first-line therapy and/or irradiation may cause pulmonary toxicity in Hodgkin lymphoma (HL) patients. Our aim was to prospectively assess effects of chest irradiation, bleomycin administration, and other factors on lung function in the treatment of patients with HL. Pulmonary function of newly diagnosed HL patients was assessed via a St. George Respiratory Questionnaire, dynamic inhalation lung scintigraphy, spirometry, and an assessment of the diffusion capacity of the lung for carbon monoxide (DLCO) before, during, and after treatment. Read More....